Q3 2025 Amphastar Pharmaceuticals Inc Earnings Call Transcript

Nov 6, 2025 / 10:00 PM GMT

Release Date Price: $24.23 (-4.27%)

Transcript 10-Q8-K

Key Points

Positve

Amphastar Pharmaceuticals Inc (AMPH) achieved net revenues of $191.8 million for the third quarter, with a GAAP net income of $17.3 million.
The company's core products, Bexsemi and Primatene Mist, showed strong performance, with Bexsemi sales up 14% year over year and Primatene Mist sales up 11%.
Amphastar Pharmaceuticals Inc (AMPH) expanded its proprietary pipeline through an exclusive in-licensing agreement with Nanjing Angi Biotechnology, securing rights to three novel peptide candidates.
The company received FDA approval for its iron sucrose injection, AMP 002, which is now commercially available in the United States.
Amphastar Pharmaceuticals Inc (AMPH) is on track to launch several high-impact regulatory programs, including AMP 007 inhalation and generic teraparatide product AMP 015, by 2026.

Negative

Glucagon injection sales declined by 49% due to increased competition and a shift to ready-to-use glucagon products.
Epinephrine sales decreased by 12% due to increased competition on multi-dose vial products.
Cost of revenues increased to $93.2 million, with gross margins declining to 51.4% from 53.3% in the previous year's period.
General and administrative spending increased significantly due to a litigation provision related to a recent jury verdict against the company.
Net income decreased to $17.4 million from $40.4 million in the third quarter of 2024, reflecting challenges in maintaining profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMPH.OQ - Amphastar Pharmaceuticals Inc
Q3 2025 Amphastar Pharmaceuticals Inc Earnings Call
Nov 06, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Amphastar Pharmaceuticals Inc. 3rd quarter earnings call.

At this time, all participants are in a listen-only mode.

A question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press 0 on your telephone keypad.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for the future periods, are forward-looking statements.

These statements are based solely on information that is now available to us.

We encourage you to review the session

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.